153 related articles for article (PubMed ID: 31756326)
1. A GIP/xenin hybrid in combination with exendin-4 improves metabolic status in db/db diabetic mice and promotes enduring antidiabetic benefits in high fat fed mice.
Craig SL; Perry RA; Vyavahare SS; Ng MT; Gault VA; Flatt PR; Irwin N
Biochem Pharmacol; 2020 Jan; 171():113723. PubMed ID: 31756326
[TBL] [Abstract][Full Text] [Related]
2. A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice.
Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
Peptides; 2018 Feb; 100():202-211. PubMed ID: 29412820
[TBL] [Abstract][Full Text] [Related]
3. Antidiabetic effects and sustained metabolic benefits of sub-chronic co-administration of exendin-4/gastrin and xenin-8-Gln in high fat fed mice.
Hasib A; Khan D; Craig SL; Gault VA; Flatt PR; Irwin N
Eur J Pharmacol; 2019 Dec; 865():172733. PubMed ID: 31614140
[TBL] [Abstract][Full Text] [Related]
4. Characterisation and antidiabetic utility of a novel hybrid peptide, exendin-4/gastrin/xenin-8-Gln.
Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
Eur J Pharmacol; 2018 Sep; 834():126-135. PubMed ID: 30025814
[TBL] [Abstract][Full Text] [Related]
5. An enzymatically stable GIP/xenin hybrid peptide restores GIP sensitivity, enhances beta cell function and improves glucose homeostasis in high-fat-fed mice.
Hasib A; Ng MT; Gault VA; Khan D; Parthsarathy V; Flatt PR; Irwin N
Diabetologia; 2017 Mar; 60(3):541-552. PubMed ID: 28004148
[TBL] [Abstract][Full Text] [Related]
6. A novel neurotensin/xenin fusion peptide enhances β-cell function and exhibits antidiabetic efficacy in high-fat fed mice.
Perry RA; Craig SL; Gault VA; Flatt PR; Irwin N
Biosci Rep; 2021 Aug; 41(8):. PubMed ID: 34370015
[TBL] [Abstract][Full Text] [Related]
7. Ψ-Xenin-6 enhances sitagliptin effectiveness, but does not improve glucose tolerance.
Craig SL; Gault VA; Hamscher G; Irwin N
J Endocrinol; 2020 May; 245(2):219-230. PubMed ID: 32130206
[TBL] [Abstract][Full Text] [Related]
8. Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic mice.
Millar PJ; Pathak V; Moffett RC; Pathak NM; Bjourson AJ; O'Kane MJ; Flatt PR; Gault VA
Mol Cell Endocrinol; 2016 Jan; 420():37-45. PubMed ID: 26607806
[TBL] [Abstract][Full Text] [Related]
9. The methionine aminopeptidase 2 inhibitor, TNP-470, enhances the antidiabetic properties of sitagliptin in mice by upregulating xenin.
Craig SL; Gault VA; Flatt PR; Irwin N
Biochem Pharmacol; 2021 Jan; 183():114355. PubMed ID: 33279496
[TBL] [Abstract][Full Text] [Related]
10. Exendin-4(Lys
Hasib A; Ng MT; Tanday N; Craig SL; Gault VA; Flatt PR; Irwin N
Diabetes Metab Res Rev; 2019 Mar; 35(3):e3106. PubMed ID: 30499633
[TBL] [Abstract][Full Text] [Related]
11. Biological Activity and Antidiabetic Potential of C-Terminal Octapeptide Fragments of the Gut-Derived Hormone Xenin.
Martin CM; Parthsarathy V; Hasib A; Ng MT; McClean S; Flatt PR; Gault VA; Irwin N
PLoS One; 2016; 11(3):e0152818. PubMed ID: 27032106
[TBL] [Abstract][Full Text] [Related]
12. Xenin-25[Lys13PAL]: a novel long-acting acylated analogue of xenin-25 with promising antidiabetic potential.
Gault VA; Martin CM; Flatt PR; Parthsarathy V; Irwin N
Acta Diabetol; 2015 Jun; 52(3):461-71. PubMed ID: 25374384
[TBL] [Abstract][Full Text] [Related]
13. A novel chemically modified analogue of xenin-25 exhibits improved glucose-lowering and insulin-releasing properties.
Parthsarathy V; Irwin N; Hasib A; Martin CM; McClean S; Bhat VK; Ng MT; Flatt PR; Gault VA
Biochim Biophys Acta; 2016 Apr; 1860(4):757-64. PubMed ID: 26802310
[TBL] [Abstract][Full Text] [Related]
14. Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice.
Irwin N; Hunter K; Montgomery IA; Flatt PR
Diabetes Obes Metab; 2013 Jul; 15(7):650-9. PubMed ID: 23388064
[TBL] [Abstract][Full Text] [Related]
15. Effects of long-acting GIP, xenin and oxyntomodulin peptide analogues on alpha-cell transdifferentiation in insulin-deficient diabetic Glu
Sarnobat D; Moffett RC; Gault VA; Tanday N; Reimann F; Gribble FM; Flatt PR; Irwin N
Peptides; 2020 Mar; 125():170205. PubMed ID: 31738969
[TBL] [Abstract][Full Text] [Related]
16. Xenin-25 amplifies GIP-mediated insulin secretion in humans with normal and impaired glucose tolerance but not type 2 diabetes.
Wice BM; Reeds DN; Tran HD; Crimmins DL; Patterson BW; Dunai J; Wallendorf MJ; Ladenson JH; Villareal DT; Polonsky KS
Diabetes; 2012 Jul; 61(7):1793-800. PubMed ID: 22522617
[TBL] [Abstract][Full Text] [Related]
17. Beneficial metabolic effects of dietary epigallocatechin gallate alone and in combination with exendin-4 in high fat diabetic mice.
Pathak NM; Millar PJB; Pathak V; Flatt PR; Gault VA
Mol Cell Endocrinol; 2018 Jan; 460():200-208. PubMed ID: 28754350
[TBL] [Abstract][Full Text] [Related]
18. Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes.
Tanday N; English A; Lafferty RA; Flatt PR; Irwin N
Front Endocrinol (Lausanne); 2021; 12():674704. PubMed ID: 34054734
[TBL] [Abstract][Full Text] [Related]
19. Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential.
Pathak NM; Pathak V; Gault VA; McClean S; Irwin N; Flatt PR
Biochem Pharmacol; 2018 Sep; 155():264-274. PubMed ID: 30028989
[TBL] [Abstract][Full Text] [Related]
20. Enzymatically stable analogue of the gut-derived peptide xenin on beta-cell transdifferentiation in high fat fed and insulin-deficient Ins1
Tanday N; Moffett RC; Gault VA; Flatt PR; Irwin N
Diabetes Metab Res Rev; 2021 Mar; 37(3):e3384. PubMed ID: 32662136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
